ROSUVAS 5 Mg Tablet


Brand Name : ROSUVAS 5 Mg Tablet
Pharmaceuticals : Ranbaxy Laboratories Limited
Generic Name :

Film coated tablet:

Rosuvastin calcium equivalent to 5 mg Rosuvastatin 

Type of Medicine : Antihyperlipidemic, HMG-COA Reductase Inhibitor
Uses :
  • Atherosclerosis.
  • High Cholesterol.
  • Homozygous familial hypercholesterolemia.
  • Heterozygous familial hypercholesterolemia.
  • Hyperlipoproteinemia.
  • Hyperlipoproteinemia Type IIa, Elevated LDL.
  • Hyperlipoproteinemia Type IIb, Elevated LDL VLDL.
  • Hyperlipoproteinemia Type III, Elevated beta –VLDL IDL.
  • Hyperlipoproteinemia Type IV, Elevated VLDL.
  • Prevention of cardiovascular disease.

 

Side Effects :

Adverse effects are generally mild and transient. As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.

Some adverse effect seen with this drug is as follow:

Myalgia, asthenia, diabetes mellitus, headache, dizziness, constipation, nausea, abdominal pains are common side effect of Rosuvastatin.


Hypersensitivity reactions including angioedema, pruritus, rash and urticaria, pancreatitis, myopathy (including myositis) and rhabdomyolysis are rarely seen side effect of Rosuvastatin.

Contraindications :
  • Hypersensitive to Rosuvastatin or to any of the excipient. Liver disease.
  • Severe renal impairment. Myopathy.
  • Patient receiving concomitant cyclosporine. Pregnancy and lactation.
  • 40 mg dose is contraindicated in the patient with pre disposing factor for myopathy / rhabdomyolysis, pediatrics.
Doses Form Available :

Tablet

Dose Available :
  • The recommended starting dose is 10 mg with titration to 20 mg only if necessary. Caution is advices when increasing the dose to 40 mg.
  • Safety and efficacy of doses greater than 20 mg have not been studied in children and adolescents.
  • Rosuvastatin is not recommended to use in the children under 10 years old.
  • A start dose of 5 mg is recommended in patients >70 years .No other dose adjustment is necessary in relation to age.
  • No dose adjustment is necessary in patients with mild to moderate renal impairment. The 40 mg dose is contraindicated in patients with moderate renal impairment.
  • The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients because pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians
Precautions :

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Should not be used in any patient with an acute or serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).

Should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease. It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Rosuvastatin should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal.

In patients with secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Rosuvastin.